DK1852433T3 - Carbazolderivat, solvate deraf eller farmaceutisk acceptabelt salt deraf - Google Patents
Carbazolderivat, solvate deraf eller farmaceutisk acceptabelt salt derafInfo
- Publication number
- DK1852433T3 DK1852433T3 DK05799893.2T DK05799893T DK1852433T3 DK 1852433 T3 DK1852433 T3 DK 1852433T3 DK 05799893 T DK05799893 T DK 05799893T DK 1852433 T3 DK1852433 T3 DK 1852433T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- carbazole derivatives
- solvates
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000012453 solvate Substances 0.000 title abstract 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 abstract 1
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000000055 hyoplipidemic effect Effects 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001603 reducing effect Effects 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004316872 | 2004-10-29 | ||
| PCT/JP2005/020250 WO2006046779A1 (ja) | 2004-10-29 | 2005-10-28 | カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1852433T3 true DK1852433T3 (da) | 2012-01-30 |
Family
ID=36227999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05799893.2T DK1852433T3 (da) | 2004-10-29 | 2005-10-28 | Carbazolderivat, solvate deraf eller farmaceutisk acceptabelt salt deraf |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8329913B2 (OSRAM) |
| EP (1) | EP1852433B1 (OSRAM) |
| JP (1) | JP3997491B2 (OSRAM) |
| KR (1) | KR101223820B1 (OSRAM) |
| CN (1) | CN101048402B (OSRAM) |
| AT (1) | ATE534646T1 (OSRAM) |
| AU (1) | AU2005297800B2 (OSRAM) |
| CA (1) | CA2585642C (OSRAM) |
| CY (1) | CY1112649T1 (OSRAM) |
| DK (1) | DK1852433T3 (OSRAM) |
| ES (1) | ES2378177T3 (OSRAM) |
| PL (1) | PL1852433T3 (OSRAM) |
| PT (1) | PT1852433E (OSRAM) |
| SI (1) | SI1852433T1 (OSRAM) |
| TW (1) | TW200635922A (OSRAM) |
| WO (1) | WO2006046779A1 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393181B2 (en) | 2004-09-17 | 2008-07-01 | The Penn State Research Foundation | Expandable impeller pump |
| WO2007112033A2 (en) | 2006-03-23 | 2007-10-04 | The Penn State Research Foundation | Heart assist device with expandable impeller pump |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| KR20100033419A (ko) | 2007-07-19 | 2010-03-29 | 메타볼렉스, 인코포레이티드 | 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체 |
| JP5815516B2 (ja) | 2009-07-01 | 2015-11-17 | ザ・ペン・ステイト・リサーチ・ファウンデイションＴｈｅ Ｐｅｎｎ Ｓｔａｔｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | 拡張可能なカニューレを備える血液ポンプ |
| US8410127B2 (en) | 2009-10-01 | 2013-04-02 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| ES2676209T3 (es) | 2010-06-23 | 2018-07-17 | Metabolex Inc. | Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| CN102382037B (zh) * | 2010-09-03 | 2016-01-20 | 中国医学科学院药物研究所 | 苯丙酸类化合物及其制法和药物用途 |
| US8485961B2 (en) | 2011-01-05 | 2013-07-16 | Thoratec Corporation | Impeller housing for percutaneous heart pump |
| US8597170B2 (en) | 2011-01-05 | 2013-12-03 | Thoratec Corporation | Catheter pump |
| WO2012094641A2 (en) | 2011-01-06 | 2012-07-12 | Thoratec Corporation | Percutaneous heart pump |
| US8591393B2 (en) | 2011-01-06 | 2013-11-26 | Thoratec Corporation | Catheter pump |
| GB2504176A (en) | 2012-05-14 | 2014-01-22 | Thoratec Corp | Collapsible impeller for catheter pump |
| DE102013008159A1 (de) | 2012-05-14 | 2013-11-14 | Thoratec Corporation | Mantelsystem für Katheterpumpe |
| US9327067B2 (en) | 2012-05-14 | 2016-05-03 | Thoratec Corporation | Impeller for catheter pump |
| US9446179B2 (en) | 2012-05-14 | 2016-09-20 | Thoratec Corporation | Distal bearing support |
| US9872947B2 (en) | 2012-05-14 | 2018-01-23 | Tc1 Llc | Sheath system for catheter pump |
| US8721517B2 (en) | 2012-05-14 | 2014-05-13 | Thoratec Corporation | Impeller for catheter pump |
| US9358329B2 (en) | 2012-07-03 | 2016-06-07 | Thoratec Corporation | Catheter pump |
| US9421311B2 (en) | 2012-07-03 | 2016-08-23 | Thoratec Corporation | Motor assembly for catheter pump |
| EP4186557A1 (en) | 2012-07-03 | 2023-05-31 | Tc1 Llc | Motor assembly for catheter pump |
| US11033728B2 (en) | 2013-03-13 | 2021-06-15 | Tc1 Llc | Fluid handling system |
| US11077294B2 (en) | 2013-03-13 | 2021-08-03 | Tc1 Llc | Sheath assembly for catheter pump |
| EP4122520A1 (en) | 2013-03-13 | 2023-01-25 | Tc1 Llc | Fluid handling system |
| US9308302B2 (en) | 2013-03-15 | 2016-04-12 | Thoratec Corporation | Catheter pump assembly including a stator |
| US20160030649A1 (en) | 2013-03-15 | 2016-02-04 | Thoratec Corporation | Catheter pump assembly including a stator |
| US9827356B2 (en) | 2014-04-15 | 2017-11-28 | Tc1 Llc | Catheter pump with access ports |
| WO2015160943A1 (en) | 2014-04-15 | 2015-10-22 | Thoratec Corporation | Sensors for catheter pumps |
| US10583232B2 (en) | 2014-04-15 | 2020-03-10 | Tc1 Llc | Catheter pump with off-set motor position |
| EP4417244A3 (en) | 2014-04-15 | 2024-10-16 | Tc1 Llc | Catheter pump introducer system |
| WO2016028644A1 (en) | 2014-08-18 | 2016-02-25 | Thoratec Corporation | Guide features for percutaneous catheter pump |
| US9675738B2 (en) | 2015-01-22 | 2017-06-13 | Tc1 Llc | Attachment mechanisms for motor of catheter pump |
| EP3247421B1 (en) | 2015-01-22 | 2019-10-02 | Tc1 Llc | Motor assembly with heat exchanger for catheter pump |
| EP3247420B1 (en) | 2015-01-22 | 2019-10-02 | Tc1 Llc | Reduced rotational mass motor assembly for catheter pump |
| US9907890B2 (en) | 2015-04-16 | 2018-03-06 | Tc1 Llc | Catheter pump with positioning brace |
| US11160970B2 (en) | 2016-07-21 | 2021-11-02 | Tc1 Llc | Fluid seals for catheter pump motor assembly |
| WO2018017683A1 (en) | 2016-07-21 | 2018-01-25 | Thoratec Corporation | Gas-filled chamber for catheter pump motor assembly |
| US10292983B2 (en) | 2016-08-03 | 2019-05-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| EP3691648A1 (en) | 2017-10-06 | 2020-08-12 | Gilead Sciences, Inc. | Combination therapy comprising an acc inhibitor |
| US12522850B2 (en) | 2019-12-19 | 2026-01-13 | Abiochem Biotechnology (Group) Co., Ltd. | Fluoroacetate dehalogenase mutant and application thereof |
| CN116327749A (zh) * | 2023-04-21 | 2023-06-27 | 重庆医科大学 | Gw9662制备治疗非酒精性脂肪性肝炎药物的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ24197A3 (en) | 1994-07-27 | 1997-08-13 | Sankyo Co | Heterocyclic compounds, usable as allosteric efectors in muscarine receptors |
| CA2269203A1 (en) | 1996-10-30 | 1998-05-07 | Nicholas James Bach | Substituted tricyclics |
| MY125942A (en) * | 1999-09-07 | 2006-09-29 | Upjohn Co | Aminoalkoxy carbazoles for the treatment of cns diseases |
| AU7559600A (en) | 1999-10-15 | 2001-04-23 | Shionogi & Co., Ltd. | V type and/or x type spla2 inhibitors |
| US20040102442A1 (en) | 2000-06-29 | 2004-05-27 | Kohji Hanasaki | Remedies for alzheimer's disease |
| ES2294003T3 (es) | 2000-06-29 | 2008-04-01 | Anthera Pharmaceuticals, Inc. | Remedios contra el cancer. |
| AU2001267825A1 (en) | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Remedies for cirrhosis |
| TWI314457B (OSRAM) | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
| DE60218155D1 (de) | 2001-03-28 | 2007-03-29 | Lilly Co Eli | Substituierte carbazole als inhibitoren von spla2 |
| WO2004024939A2 (en) | 2002-09-13 | 2004-03-25 | Georgetown University | Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof |
| US7268157B2 (en) * | 2002-11-26 | 2007-09-11 | Shenzhen Chipscreen Biosciences, Ltd. | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity |
-
2005
- 2005-10-28 US US11/666,631 patent/US8329913B2/en not_active Expired - Fee Related
- 2005-10-28 DK DK05799893.2T patent/DK1852433T3/da active
- 2005-10-28 ES ES05799893T patent/ES2378177T3/es not_active Expired - Lifetime
- 2005-10-28 KR KR1020077009734A patent/KR101223820B1/ko not_active Expired - Fee Related
- 2005-10-28 AU AU2005297800A patent/AU2005297800B2/en not_active Ceased
- 2005-10-28 JP JP2006542433A patent/JP3997491B2/ja not_active Expired - Fee Related
- 2005-10-28 EP EP05799893A patent/EP1852433B1/en not_active Expired - Lifetime
- 2005-10-28 WO PCT/JP2005/020250 patent/WO2006046779A1/ja not_active Ceased
- 2005-10-28 CA CA2585642A patent/CA2585642C/en not_active Expired - Fee Related
- 2005-10-28 SI SI200531453T patent/SI1852433T1/sl unknown
- 2005-10-28 AT AT05799893T patent/ATE534646T1/de active
- 2005-10-28 TW TW094137797A patent/TW200635922A/zh not_active IP Right Cessation
- 2005-10-28 CN CN2005800370489A patent/CN101048402B/zh not_active Expired - Fee Related
- 2005-10-28 PT PT05799893T patent/PT1852433E/pt unknown
- 2005-10-28 PL PL05799893T patent/PL1852433T3/pl unknown
-
2012
- 2012-01-25 CY CY20121100086T patent/CY1112649T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1852433B1 (en) | 2011-11-23 |
| ATE534646T1 (de) | 2011-12-15 |
| US20100286210A1 (en) | 2010-11-11 |
| AU2005297800B2 (en) | 2011-02-03 |
| TW200635922A (en) | 2006-10-16 |
| CA2585642A1 (en) | 2006-05-04 |
| KR101223820B1 (ko) | 2013-01-17 |
| EP1852433A4 (en) | 2010-07-21 |
| KR20070072554A (ko) | 2007-07-04 |
| PT1852433E (pt) | 2012-02-08 |
| TWI359148B (OSRAM) | 2012-03-01 |
| WO2006046779A1 (ja) | 2006-05-04 |
| JP3997491B2 (ja) | 2007-10-24 |
| CN101048402A (zh) | 2007-10-03 |
| PL1852433T3 (pl) | 2012-05-31 |
| US8329913B2 (en) | 2012-12-11 |
| ES2378177T3 (es) | 2012-04-09 |
| CA2585642C (en) | 2013-04-02 |
| AU2005297800A1 (en) | 2006-05-04 |
| CN101048402B (zh) | 2011-11-09 |
| JPWO2006046779A1 (ja) | 2008-05-22 |
| SI1852433T1 (sl) | 2012-06-29 |
| EP1852433A1 (en) | 2007-11-07 |
| CY1112649T1 (el) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1852433T3 (da) | Carbazolderivat, solvate deraf eller farmaceutisk acceptabelt salt deraf | |
| AP804A (en) | APO-B-secretion/MTP inhibitory amides. | |
| IL193321A0 (en) | Compounds for the treatment of metabolic disorders | |
| NZ590355A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| WO2009123164A1 (ja) | 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体 | |
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| NO20081821L (no) | Forbindelser for behandling av metabolske forstyrrelser | |
| PE20020476A1 (es) | Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos | |
| MX2011012108A (es) | Sal de clorhidrato de ((1s, 2s, 4r)-4-{4-[(1s)-2, 3-dihidro-1h-inden-1-ilamino]-7h-pirrolo [2, 3-d]pirimidin-7-il}-2 -hidroxiciclopentil)metilsulfamato. | |
| WO2009133834A1 (ja) | 血管内皮リパーゼ阻害活性を有するケトアミド誘導体 | |
| WO2007099162A3 (fr) | Derive de resveratrol a longue chaine hydroxylee utiles comme neurotrophiques | |
| FR2929116B1 (fr) | Composition cosmetique comprenant un derive d'acide imido-percarboxylique et un ester n-acyle d'acide amine | |
| MXPA05011592A (es) | Compuestos para el tratamiento de trastornos metabolicos. | |
| EP1618086A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER | |
| ZA200805740B (en) | Novel polyunsaturated compounds, method for preparing same and compositions containing same | |
| RU2012129932A (ru) | Средство для предотвращения или ослабления пигментации | |
| WO2008062830A1 (en) | Spiroquinone compound and pharmaceutical composition | |
| CY1110613T1 (el) | Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων | |
| EP1994007A4 (en) | SOLID PHASE SYNTHESIS OF ACRIDINE DERIVATIVES | |
| RU2009123645A (ru) | Способы повышения биодоступности ингибитора ренина | |
| EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций | |
| Wang et al. | Synthesis and biological evaluation of ezetimibe analogs as possible cholesterol absorption inhibitors | |
| CA2643300A1 (en) | Trans-fused chromenoisoquinolines, synthesis and methods for use | |
| TW200612912A (en) | Benzyloxy derivatives as maob inhibitors | |
| RU2007146364A (ru) | Средство для ингибирования накопления висцеральной жировой ткани |